METHODS AND COMPOSITIONS FOR ASSESSMENT OF PULMONARY FUNCTION AND DISORDERS
First Claim
Patent Images
1. A method of determining a subject'"'"'s risk of developing asthma comprising analysing a sample from said subject for the presence or absence of at least one polymorphism selected from the group consisting of:
- +489 G/A in the gene encoding Tissue Necrosis Factor α
(TNF α
);
Tyr 113 His T/C (Exon3) in the gene encoding Microsomal epoxide hydrolase (MEH); and
one or more polymorphisms which are in linkage disequilibrium with +489 G/A in the gene encoding TNF α
or Tyr 113 His T/C (Exon3) in the gene encoding MEH;
wherein the presence or absence of said at least one polymorphism is indicative of the subject'"'"'s risk of developing asthma.
1 Assignment
0 Petitions
Accused Products
Abstract
The present invention provides methods for the assessment risk of developing asthma in smokers and non-smokers using analysis of genetic polymorphisms. The present invention also relates to the use of genetic polymorphisms in assessing a subject'"'"'s risk of developing asthma. Nucleotide probes and primers, kits, and microarrays suitable for such assessment are also provided.
-
Citations
17 Claims
-
1. A method of determining a subject'"'"'s risk of developing asthma comprising analysing a sample from said subject for the presence or absence of at least one polymorphism selected from the group consisting of:
-
+489 G/A in the gene encoding Tissue Necrosis Factor α
(TNF α
);Tyr 113 His T/C (Exon3) in the gene encoding Microsomal epoxide hydrolase (MEH); and one or more polymorphisms which are in linkage disequilibrium with +489 G/A in the gene encoding TNF α
or Tyr 113 His T/C (Exon3) in the gene encoding MEH;wherein the presence or absence of said at least one polymorphism is indicative of the subject'"'"'s risk of developing asthma. - View Dependent Claims (2, 3, 4, 13)
-
-
5. A method of assessing a subject'"'"'s risk of developing asthma said method comprising the steps:
-
(i) determining the presence or absence of at least one protective polymorphism associated with a reduced risk of developing asthma; and (ii) in the absence of at least one protective polymorphism, determining the presence or absence of at least one susceptibility polymorphism associated with an increased risk of developing asthma; wherein the presence of at least one protective polymorphism is indicative of a reduced risk of developing asthma, and wherein the absence of at least one protective polymorphism in combination with the presence of at least one susceptibility polymorphism is indicative of an increased risk of developing asthma. - View Dependent Claims (6, 7, 8, 9, 10, 11)
-
-
12. A method of determining a subject'"'"'s risk of developing asthma, comprising analysing a sample from said subject for the presence of two or more polymorphisms selected from the group consisting of:
-
+489 G/A in the gene encoding Tissue Necrosis Factor α
(TNF α
);Tyr 113 His T/C (Exon3) in the gene encoding Microsomal epoxide hydrolase (MEH); Ile 105 Val A/G in the gene encoding Glutathione S Transferase P (GSTP1); Arg 197 Gln A/G in the gene encoding N-acetyltransferase 2 (NAT2); −
159 C/T in the gene encoding CD14;+2151 G/C in the gene encoding ADAM 33; −
403 C/T in the gene encoding RANTES;E469K A/G in the gene encoding Intra-cellular adhesion molecule (ICAM1); and one or more polymorphisms which are in linkage disequilibrium with +489 G/A in the gene encoding TNF α
, Tyr 113 His T/C (Exon3) in the gene encoding MEH, Ile 105 Val A/G in the gene encoding GSTP1, Arg 197 Gln A/G in the gene encoding NAT2, −
159 C/T in the gene encoding CD14, +2151 G/C in the gene encoding ADAM 33, −
403 C/T in the gene encoding RANTES, or E469K A/G in the gene encoding ICAM1.
-
-
14. A method of determining a subject'"'"'s risk of developing asthma, said method comprising the steps:
-
(i) providing the result of one or more genetic tests of a sample from said subject; and (ii) analysing the result for the presence or absence of one or more polymorphisms selected from the group consisting of; +489 G/A in the gene encoding Tissue Necrosis Factor α
(TNF α
);Tyr 113 His T/C (Exon3) in the gene encoding Microsomal epoxide hydrolase (MEH); and one or more polymorphisms which are in linkage disequilibrium with +489 G/A in the gene encoding TNF α
or Tyr 113 His T/C (Exon3) in the gene encoding MEH;wherein a result indicating the presence or absence of one or more of said polymorphisms is indicative of the subject'"'"'s risk of developing asthma. - View Dependent Claims (15, 16)
-
-
17-41. -41. (canceled)
Specification